Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Spruce Biosciences (Nasdaq: SPRB) has been added to the Russell 3000® Index, effective with the opening of U.S. equity markets on the 2026 reconstitution date. This also brings automatic inclusion in the Russell 2000® Index as a small-cap constituent.
The company is a late-stage, precommercial biopharma advancing tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B (MPS IIIB), with a planned BLA submission and potential U.S. FDA approval and launch.
Spruce Biosciences (Nasdaq: SPRB) appointed Agnieszka “AJ” Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs to lead medical affairs and scientific engagement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B.
On June 22, 2026, she also received 3,800 RSUs vesting over four years under Spruce’s 2026 Inducement Plan.
Spruce Biosciences (Nasdaq: SPRB) appointed Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller. Both bring over 20 years of biotech and finance experience as Spruce prepares for a potential U.S. FDA approval and commercial launch of TA-ERT for Sanfilippo Syndrome Type B.
On June 15, 2026, each executive received an inducement grant of 3,500 RSUs, vesting annually over four years under the 2026 Inducement Plan.
Spruce Biosciences (Nasdaq: SPRB) reported long-term data for investigational tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) from 22 patients followed for up to six years.
Weekly TA-ERT rapidly normalized CSF HS-NRE and stabilized cognition, communication, motor skills, and brain and organ volumes versus untreated natural history patients, with about 6,000 intracerebroventricular doses showing a safety profile generally consistent with this route.
Spruce Biosciences (Nasdaq: SPRB) will present long-term data on its investigational therapy tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) at the 18th International MPS & Related Lysosomal Diseases Symposium, held June 4-7, 2026, in Florence, Italy.
The oral poster presentation by Nicole Muschol, M.D. (Poster 75) is scheduled for June 6, 2026, from 10:00-10:10 a.m. CEST, and is titled to highlight long-term administration, heparan sulfate reduction, and stabilization of cognitive function and cortical gray matter volume.
Spruce Biosciences (Nasdaq: SPRB) will participate in two June 2026 industry events. Management will present and host 1x1 meetings at the Jefferies Global Healthcare Conference on June 4 in New York, and attend the BIO International Convention for 1x1 meetings June 24-25 in San Diego.
Spruce Biosciences (Nasdaq: SPRB) reported Q1 2026 results and TA-ERT program progress for MPS IIIB. Long-term TA-ERT data presented at WORLDSymposium™ showed rapid, durable cerebrospinal fluid heparan sulfate reductions and stabilization of cognitive function and cortical gray matter volume versus natural history.
The company is preparing a planned TA-ERT BLA submission in Q4 2026 and building commercial and development leadership ahead of a potential U.S. launch. Spruce closed a $69.0 million underwritten public offering and secured a term loan facility of up to $50.0 million, extending its cash runway into the second half of 2027. Q1 2026 operating expenses fell to $12.0 million and net loss was $12.3 million, with cash and cash equivalents of $54.1 million on March 31, 2026 and a preliminary $107.3 million on April 30, 2026.
Spruce Biosciences (Nasdaq: SPRB) appointed Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations, supporting a planned commercial launch of tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) targeted next year. Each executive will receive 3,500 RSUs vesting annually over four years under an inducement plan filed on Form S-8.
The hires bring extensive rare-disease launch experience and are intended to build market access, pricing, analytics, and launch infrastructure ahead of potential approval.
Spruce Biosciences (Nasdaq: SPRB) priced an underwritten public offering of 1,150,000 common shares at $50.00 per share and pre-funded warrants to purchase 50,000 shares at $49.99 per warrant, producing expected gross proceeds of $60 million.
The offering is expected to close on April 22, 2026, subject to customary closing conditions, and underwriters hold a 30-day option for up to 180,000 additional shares.
Spruce Biosciences (NASDAQ: SPRB) commenced an underwritten public offering of common stock or pre-funded warrants on April 20, 2026. The offering includes a 30-day underwriter option to purchase up to 15% additional shares. The offering is subject to market conditions and final prospectus terms.
Joint book-runners are Leerink Partners, Guggenheim Securities, and Oppenheimer; Jones and Craig-Hallum are co-managers. Securities are offered under a Form S-3 shelf registration declared effective on November 26, 2025. No assurance as to completion, size, or terms.